Combination Drug/Diagnostic Products: Pathways to R&D and Commercial Success

By Hermann A.M. Mucke, PhD
Michael S. Goodman

SURVEY QUESTIONS

1. Please classify your organization.
 
2. How many drugs does your company currently have in development or on the market that are or will be paired with a companion diagnostic?
 
3. In the next three years how many drugs does your company expect to have in development or on the market that will be paired with a companion diagnostic?
 
4. Do you believe that large pharma is holding off on combination drug/diagnostic adoption due to concern about losing the blockbuster model?
 
5. Do you believe that there are only a few select situations where the confluence of disease type drug characteristics and market need provides the basis for a successful combination drug/diagnostic application?
 
6. Which do you believe is the best approach to a combination drug/diagnostic?
 
7. Select the characteristic(s) of a disease area that you believe best qualify it for a combination drug/diagnostic application. Please select all that apply.
 
8. Select the disease area(s) best suited for a combination drug/diagnostic product.
 
9. Which industry segment will be the driving force over the next 3 years for bringing combination drug/diagnostic products to the market?
 
10. Select the most attractive incentive that will motivate therapeutically-focused companies to pursue a combination drug/diagnostic strategy.
 
11. Name the key therapeutically-focused companies with respect to (1) their ability to execute and (2) the completeness of their vision which you believe are pursuing a combination drug/diagnostic strategy.
 
12. Name the key diagnostic-focused companies with respect to (1) their ability to execute and (2) the completeness of their vision which you believe are pursuing a combination drug/diagnostic strategy.
 
13. With respect to companies pursuing a combination drug/diagnostic strategy what do you believe the prevailing strategy will be for adopting the diagnostic element of a combination approach?
 
14. What do you believe is the correct approach to combination product development?